EA028395B1 - Способы получения фенилацетата l-орнитина - Google Patents
Способы получения фенилацетата l-орнитина Download PDFInfo
- Publication number
- EA028395B1 EA028395B1 EA201390403A EA201390403A EA028395B1 EA 028395 B1 EA028395 B1 EA 028395B1 EA 201390403 A EA201390403 A EA 201390403A EA 201390403 A EA201390403 A EA 201390403A EA 028395 B1 EA028395 B1 EA 028395B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ornithine
- salt
- phenylacetate
- benzoate
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/32—Phenylacetic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39058510P | 2010-10-06 | 2010-10-06 | |
| PCT/US2011/054983 WO2012048043A1 (en) | 2010-10-06 | 2011-10-05 | Methods of making l-ornithine phenyl acetate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201390403A1 EA201390403A1 (ru) | 2013-09-30 |
| EA028395B1 true EA028395B1 (ru) | 2017-11-30 |
Family
ID=45928120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201390403A EA028395B1 (ru) | 2010-10-06 | 2011-10-05 | Способы получения фенилацетата l-орнитина |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8946473B2 (enExample) |
| EP (1) | EP2625162B1 (enExample) |
| JP (1) | JP6087284B2 (enExample) |
| KR (1) | KR101888215B1 (enExample) |
| CN (1) | CN103502203B (enExample) |
| AU (1) | AU2011312042B2 (enExample) |
| BR (1) | BR112013008054B1 (enExample) |
| CA (1) | CA2813563C (enExample) |
| EA (1) | EA028395B1 (enExample) |
| ES (1) | ES2720148T3 (enExample) |
| IL (1) | IL225512A (enExample) |
| MX (1) | MX360062B (enExample) |
| NZ (1) | NZ609191A (enExample) |
| SG (1) | SG189231A1 (enExample) |
| TR (1) | TR201903978T4 (enExample) |
| WO (1) | WO2012048043A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5116479B2 (ja) | 2004-11-26 | 2013-01-09 | ユーシーエル ビジネス ピーエルシー | オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物 |
| ES2928586T3 (es) | 2009-04-03 | 2022-11-21 | Ocera Therapeutics Inc | Fenilacetato de L-ornitina y métodos para elaborar el mismo |
| KR101715008B1 (ko) | 2009-06-08 | 2017-03-22 | 유씨엘 비즈니스 피엘씨 | Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 |
| JP6087284B2 (ja) | 2010-10-06 | 2017-03-01 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンフェニルアセテートを製造するための方法 |
| DK3223829T3 (da) | 2014-11-24 | 2020-02-10 | Ucl Business Ltd | Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier |
| RU2755904C2 (ru) * | 2015-04-20 | 2021-09-22 | Осера Терапьютикс, Инк. | Составы l-орнитин фенилацетата |
| HK1249434A1 (zh) * | 2015-08-18 | 2018-11-02 | Ocera Therapeutics, Inc. | 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失 |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| MX389926B (es) * | 2015-11-13 | 2025-03-20 | Ocera Therapeutics Inc | Formulaciones de fenilacetato de l-ornitina |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| CA3063134A1 (en) * | 2017-05-11 | 2018-11-15 | Ocera Therapeutics, Inc. | Processes of making l-ornithine phenylacetate |
| BR112020002419A2 (pt) | 2017-08-14 | 2020-07-28 | Axcella Health Inc. | aminoácido para o tratamento de doença do fígado |
| WO2019246225A1 (en) | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| MX2021013526A (es) | 2019-05-09 | 2021-12-10 | Ocera Therapeutics Inc | Metodos de evaluacion y tratamiento de encefalopatia hepatica. |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03009902A (es) * | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio. |
| US20080119554A1 (en) * | 2004-11-26 | 2008-05-22 | Rajiv Jalan | Compositions Comprising Ornithine And Phenylacetate Or Phenylbutyrate For Treating Hepatic Encephalopathy |
| WO2010115055A1 (en) * | 2009-04-03 | 2010-10-07 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB965637A (en) | 1962-04-23 | 1964-08-06 | Tanabe Seiyaku Co | L-ornithine l-aspartate |
| NL302572A (enExample) | 1962-12-27 | |||
| GB1067742A (en) | 1963-09-16 | 1967-05-03 | Kyowa Hakko Kogyo Kk | Process for the preparation of l-ornithine l-aspartate |
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| US4100293A (en) | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids |
| US3950529A (en) | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4228099A (en) | 1978-03-17 | 1980-10-14 | The Johns Hopkins University | Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders |
| US4352814A (en) | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| DE4020980C1 (enExample) | 1990-07-02 | 1991-09-26 | Degussa Ag, 6000 Frankfurt, De | |
| US5591613A (en) | 1990-07-02 | 1997-01-07 | Degussa Aktiengesellschaft | Method for the preparation of D-arginine and L-ornithine |
| JP3127484B2 (ja) | 1991-02-28 | 2001-01-22 | 味の素株式会社 | 肝炎治療薬 |
| US5767086A (en) | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| EP0659150B1 (en) | 1992-09-09 | 1997-05-21 | FISONS plc | Pharmaceutical packaging |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP3273578B2 (ja) * | 1993-09-21 | 2002-04-08 | 第一化学薬品株式会社 | オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法 |
| US5856481A (en) | 1994-07-28 | 1999-01-05 | Syntex (U.S.A.) Inc. | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| WO1997030167A1 (en) | 1996-02-13 | 1997-08-21 | The Trustees Of The University Of Pennsylvania | Method of treating liver disorders |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6258849B1 (en) | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| CA2374273A1 (en) | 1999-05-21 | 2000-11-30 | Takeda Chemical Industries, Ltd. | Liver function controlling agents |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| JP3211824B1 (ja) | 2000-10-26 | 2001-09-25 | 味の素株式会社 | 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法 |
| TWI309162B (en) | 2001-03-15 | 2009-05-01 | Rikagaku Kenkyusho | Amino acid composition for improving functional disorder of liver |
| US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
| US20030105104A1 (en) | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| CN1383815A (zh) | 2002-05-08 | 2002-12-11 | 刘万忠 | 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法 |
| US20040152784A1 (en) | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| AU2003261825A1 (en) | 2002-08-30 | 2004-03-19 | Ajinomoto Co., Inc. | Therapeutic agent for hepatic disease |
| US20050059150A1 (en) | 2003-09-17 | 2005-03-17 | Becton, Dickinson And Company | Environments that maintain function of primary liver cells |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| JP4954867B2 (ja) | 2004-05-06 | 2012-06-20 | オステオロジックス エイ／エス | 有機金属塩類を製造するための高収率で迅速な合成法 |
| WO2006059237A1 (en) | 2004-08-30 | 2006-06-08 | Lunamed, Inc. | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| RS53324B (sr) | 2005-11-17 | 2014-10-31 | Silverstone Pharma Est. | Stabilna formulacija amorfnih soli perindoprila, postupak za njihovu pripremu, naročito industrijsku pripremu, i njihova upotreba u terapiji hipertenzije |
| CN201421432Y (zh) * | 2009-02-20 | 2010-03-10 | 山东师范大学 | 一种相干衍射成像处理装置 |
| KR101715008B1 (ko) | 2009-06-08 | 2017-03-22 | 유씨엘 비즈니스 피엘씨 | Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 |
| JP6087284B2 (ja) | 2010-10-06 | 2017-03-01 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンフェニルアセテートを製造するための方法 |
-
2011
- 2011-10-05 JP JP2013532925A patent/JP6087284B2/ja not_active Expired - Fee Related
- 2011-10-05 NZ NZ609191A patent/NZ609191A/en not_active IP Right Cessation
- 2011-10-05 WO PCT/US2011/054983 patent/WO2012048043A1/en not_active Ceased
- 2011-10-05 ES ES11831546T patent/ES2720148T3/es active Active
- 2011-10-05 KR KR1020137011664A patent/KR101888215B1/ko active Active
- 2011-10-05 MX MX2013003764A patent/MX360062B/es active IP Right Grant
- 2011-10-05 CA CA2813563A patent/CA2813563C/en active Active
- 2011-10-05 CN CN201180058441.1A patent/CN103502203B/zh not_active Expired - Fee Related
- 2011-10-05 SG SG2013024559A patent/SG189231A1/en unknown
- 2011-10-05 AU AU2011312042A patent/AU2011312042B2/en not_active Ceased
- 2011-10-05 US US13/878,146 patent/US8946473B2/en active Active
- 2011-10-05 BR BR112013008054-0A patent/BR112013008054B1/pt not_active IP Right Cessation
- 2011-10-05 EA EA201390403A patent/EA028395B1/ru not_active IP Right Cessation
- 2011-10-05 TR TR2019/03978T patent/TR201903978T4/tr unknown
- 2011-10-05 EP EP11831546.4A patent/EP2625162B1/en active Active
-
2013
- 2013-04-02 IL IL225512A patent/IL225512A/en active IP Right Grant
-
2015
- 2015-01-21 US US14/601,591 patent/US9260379B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03009902A (es) * | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio. |
| US20080119554A1 (en) * | 2004-11-26 | 2008-05-22 | Rajiv Jalan | Compositions Comprising Ornithine And Phenylacetate Or Phenylbutyrate For Treating Hepatic Encephalopathy |
| WO2010115055A1 (en) * | 2009-04-03 | 2010-10-07 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ609191A (en) | 2015-06-26 |
| TR201903978T4 (tr) | 2019-04-22 |
| KR101888215B1 (ko) | 2018-09-20 |
| ES2720148T3 (es) | 2019-07-18 |
| CN103502203B (zh) | 2016-09-07 |
| JP6087284B2 (ja) | 2017-03-01 |
| US20130211135A1 (en) | 2013-08-15 |
| SG189231A1 (en) | 2013-05-31 |
| WO2012048043A1 (en) | 2012-04-12 |
| BR112013008054A2 (pt) | 2016-06-14 |
| EP2625162A1 (en) | 2013-08-14 |
| MX2013003764A (es) | 2013-05-20 |
| MX360062B (es) | 2018-10-22 |
| AU2011312042A1 (en) | 2013-05-02 |
| JP2013542935A (ja) | 2013-11-28 |
| BR112013008054B1 (pt) | 2019-04-09 |
| US8946473B2 (en) | 2015-02-03 |
| KR20140053807A (ko) | 2014-05-08 |
| EP2625162A4 (en) | 2014-06-25 |
| US20150133684A1 (en) | 2015-05-14 |
| EA201390403A1 (ru) | 2013-09-30 |
| IL225512A0 (en) | 2013-06-27 |
| IL225512A (en) | 2017-12-31 |
| CA2813563A1 (en) | 2012-04-12 |
| CN103502203A (zh) | 2014-01-08 |
| EP2625162B1 (en) | 2019-03-13 |
| AU2011312042B2 (en) | 2015-08-20 |
| US9260379B2 (en) | 2016-02-16 |
| CA2813563C (en) | 2019-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA028395B1 (ru) | Способы получения фенилацетата l-орнитина | |
| US9061968B2 (en) | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs | |
| ES2652187T3 (es) | Fenilacetato de l-ornitina y métodos para elaborar el mismo | |
| TWI699367B (zh) | 用於製備丁基原啡因之方法 | |
| EP3115356A1 (en) | Polymorphs of bromfenac sodium and methods for preparing bromfenec sodium ploymorphs | |
| JP6275644B2 (ja) | Ｎ−［２−（｛２−［（２Ｓ）−２−シアノピロリジン−１−イル］−２−オキソエチル｝アミノ）−２−メチルプロピル］−２−メチルピラゾロ［１，５−ａ］ピリミジン−６−カルボキサミドの結晶 | |
| JP6495430B2 (ja) | ブロムフェナクナトリウムの多形体、及び、ブロムフェナクナトリウム多形体の製造方法 | |
| EP4281057A1 (en) | Methods for synthesizing substituted carboxylic acids and pharmaceutically acceptable salts thereof | |
| JP2022074008A (ja) | トレプロスチニル一水和物結晶およびその製造方法 | |
| HK1187603A (en) | Methods of making l-ornithine phenyl acetate | |
| HK1187603B (en) | Methods of making l-ornithine phenyl acetate | |
| WO2005023790A1 (en) | (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid sodium salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |